Friday, 16 October 2026European Markets

PROACTIS SA Stock Over 21% Up In The Last 5 Sessions

Loading stream...

proactis sa, a renowned source-to-pay software solutions provider based in france, recently drew attention as its shares experienced a 21.95% surge over five sessions following three successive losses. this occurred despite generally negative market sentiment, as exemplified by the three-session running decline of the cac 40 index.

current trading position

as of now, proactis sa trades at eur0.10, a figure well below its 2017 peak of eur0.15. however, taking into account their lowest point at eur0.88, the shares demonstrate an impressive resilience by remaining above this 52-week low point of eur0.08.

financial fundamentals overview

in spite of recent gains on the stock market, proactis sa's financial fundamentals reveal a mixed bag of results. over the past year, the company registered an unfavorable eps figure of eur-0.01, coupled with a less than satisfactory return on equity of -3.88%. these indicators point towards potential profitability issues, an essential concern for investors when evaluating an investment company.

technical indicators outlook

there is a silver lining to be found in the trading path of proactis sa. the company's shares have recently traded above their 50-day moving average of eur0.10. this may be interpreted as an encouraging technical indicator. nevertheless, trading continues to fall below the 200-day moving average, hinting at a long-term bearish stance in its trajectory.

revenue growth and liquidity concerns

one key concern for investors might be proactis's year-on-year quarterly revenue growth, which has seen a 3.6% decline. it is paramount for investors to closely monitor these performance indicators as they could potentially affect stock prices significantly. moreover, the company is facing weak liquidity, evident from the significantly reduced reported volume when compared to its average volume.

a prudent investment approach

considering all these factors, adopting a cautious investment strategy is the most advisable approach for both current and potential investors dealing with proactis sa stocks. they underscore the need for comprehensive financial literacy to discern promising signs as well as potential red flags.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com